Stocks & Investing
Stocks and Investing
Stocks and Investing
Mon, January 4, 2021
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Thu, December 31, 2020
[ 12:00 AM ] - United States, WOPRAI
Wed, December 30, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Tue, December 29, 2020
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Gregory Renza Downgraded (APRE) to Hold and Decreased Target to $200 on, Dec 29th, 2020
Gregory Renza of RBC Capital, Downgraded "Aprea Therapeutics, Inc." (APRE) to Hold and Decreased Target from $800 to $200 on, Dec 29th, 2020.
Gregory has made no other calls on APRE in the last 4 months.
There are 2 other peers that have a rating on APRE. Out of the 2 peers that are also analyzing APRE, 1 agrees with Gregory's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Decreased Target to $680 on, Wednesday, December 16th, 2020
This is the rating of the analyst that currently disagrees with Gregory
- Esther Hong of "Berenberg" Initiated at Strong Buy and Held Target at $740 on, Wednesday, December 16th, 2020
